<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">30849371</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>01</Month>
        <Day>06</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>03</Month>
        <Day>09</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1097-4172</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>176</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2019</Year>
              <Month>Mar</Month>
              <Day>07</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cell</Title>
          <ISOAbbreviation>Cell</ISOAbbreviation>
        </Journal>
        <ArticleTitle>VEGF in Signaling and Disease: Beyond Discovery and Development.</ArticleTitle>
        <Pagination>
          <StartPage>1248</StartPage>
          <EndPage>1264</EndPage>
          <MedlinePgn>1248-1264</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cell.2019.01.021</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0092-8674(19)30054-6</ELocationID>
        <Abstract>
          <AbstractText>The discovery of vascular endothelial-derived growth factor (VEGF) has revolutionized our understanding of vasculogenesis and angiogenesis during development and physiological homeostasis. Over a short span of two decades, our understanding of the molecular mechanisms by which VEGF coordinates neurovascular homeostasis has become more sophisticated. The central role of VEGF in the pathogenesis of diverse cancers and blinding eye diseases has also become evident. Elucidation of the molecular regulation of VEGF and the transformative development of multiple therapeutic pathways targeting VEGF directly or indirectly is a powerful case study of how fundamental research can guide innovation and translation. It is also an elegant example of how agnostic discovery and can transform our understanding of human disease. This review will highlight critical nodal points in VEGF biology, including recent developments in immunotherapy for cancer and multitarget approaches in neovascular eye disease.</AbstractText>
          <CopyrightInformation>Copyright © 2019 Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Apte</LastName>
            <ForeName>Rajendra S</ForeName>
            <Initials>RS</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, MO, USA; Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA; Department of Developmental Biology, Washington University School of Medicine, St. Louis, MO, USA. Electronic address: apte@wustl.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Daniel S</ForeName>
            <Initials>DS</Initials>
            <AffiliationInfo>
              <Affiliation>IGM Biosciences, Mountain View, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ferrara</LastName>
            <ForeName>Napoleone</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, University of California, San Diego, CA, USA; Department of Ophthalmology, University of California, San Diego, CA, USA; The Moores Cancer Center, University of California, San Diego, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>P30 EY002687</GrantID>
            <Acronym>EY</Acronym>
            <Agency>NEI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 EY019287</GrantID>
            <Acronym>EY</Acronym>
            <Agency>NEI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R21 EY026707</GrantID>
            <Acronym>EY</Acronym>
            <Agency>NEI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R21 EY028701</GrantID>
            <Acronym>EY</Acronym>
            <Agency>NEI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Cell</MedlineTA>
        <NlmUniqueID>0413066</NlmUniqueID>
        <ISSNLinking>0092-8674</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D042461">Vascular Endothelial Growth Factor A</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D042442">Vascular Endothelial Growth Factors</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012171" MajorTopicYN="N">Retinal Vessels</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D042461" MajorTopicYN="N">Vascular Endothelial Growth Factor A</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D042442" MajorTopicYN="N">Vascular Endothelial Growth Factors</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2018</Year>
          <Month>9</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2019</Year>
          <Month>1</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2019</Year>
          <Month>1</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pmc-release">
          <Year>2020</Year>
          <Month>3</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>3</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>3</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>1</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">30849371</ArticleId>
        <ArticleId IdType="mid">NIHMS1518667</ArticleId>
        <ArticleId IdType="pmc">PMC6410740</ArticleId>
        <ArticleId IdType="doi">10.1016/j.cell.2019.01.021</ArticleId>
        <ArticleId IdType="pii">S0092-8674(19)30054-6</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Adamis AP, and Shima DT (2005). The role of vascular endothelial growth factor in ocular health and disease. Retina
25, 111–118.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15689799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Algire GH, Chalkley HW, Legallais FY, and Park HD (1945). Vascular reactions of normal and malignant tissues in vivo. I. Vascular reactions of mice to wounds and to normal and neoplastic transplants. J Natl Cancer Inst
6, 73–85.</Citation>
        </Reference>
        <Reference>
          <Citation>Alitalo K, Tammela T, and Petrova TV (2005). Lymphangiogenesis in development and human disease. Nature
438, 946–953.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16355212</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Allen E, Jabouille A, Rivera LB, Lodewijckx I, Missiaen R, Steri V, Feyen K, Tawney J, Hanahan D, Michael IP, et al. (2017). Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation. Sci Transl Med
9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5554432</ArticleId>
            <ArticleId IdType="pubmed">28404866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Apte RS (2016). What Is Chronic or Persistent Diabetic Macular Edema and How Should It Be Treated?
JAMA Ophthalmol
134, 285–286.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26746003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Apte RS (2018). Gene Therapy for Retinal Degeneration. Cell
173, 5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29570997</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Apte RS, Richter J, Herndon J, and Ferguson TA (2006). Macrophages inhibit neovascularization in a murine model of age-related macular degeneration. PLoS Med
3, e310.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1539093</ArticleId>
            <ArticleId IdType="pubmed">16903779</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arjaans M, Oosting SF, Schroder CP, and de Vries EG (2013). Bevacizumab-induced vessel normalization hampers tumor uptake of antibodies--response. Cancer Res
73, 7147–7148.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24265275</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ashton N (1952). Observations on the choroidal circulation. Br J Ophthalmol
36, 465–481.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1323969</ArticleId>
            <ArticleId IdType="pubmed">12978221</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ashton N (1966). Oxygen and the growth and development of retinal vessels. In vivo and in vitro studies. The XX Francis I. Proctor Lecture. Am J Ophthalmol
62, 412–435.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">5950745</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Atkins MB, Clark JI, and Quinn DI (2017). Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions. Ann Oncol
28, 1484–1494.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28383639</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Atkins MB, Plimack ER, Puzanov I, Fishman MN, McDermott DF, Cho DC, Vaishampayan U, George S, Olencki TE, Tarazi JC, et al. (2018). Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial. Lancet Oncol
19, 405–415.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6860026</ArticleId>
            <ArticleId IdType="pubmed">29439857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Augustin HG, Koh GY, Thurston G, and Alitalo K (2009). Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol
10, 165–177.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19234476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bais C, Wu X, Yao J, Yang S, Crawford Y, McCutcheon K, Tan C, Koluman G, Vernes J-M, Eastham-Anderson J, et al. (2010). PlGF blockade does not inhibit angiogenesis during primary tumor growth. Cell
141, 166–177.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20371352</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bakall B, Folk JC, Boldt HC, Sohn EH, Stone EM, Russell SR, and Mahajan VB (2013). Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab. Am J Ophthalmol
156, 15–22 e11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23706500</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ban N, Lee TJ, Sene A, Choudhary M, Lekwuwa M, Dong Z, Santeford A, Lin JB, Malek G, Ory DS, et al. (2018). Impaired monocyte cholesterol clearance initiates age-related retinal degeneration and vision loss. JCI Insight
3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6171801</ArticleId>
            <ArticleId IdType="pubmed">30185655</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A, and Marme D (1996). Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood
87, 3336–3343.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8605350</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, Eichler AF, Drappatz J, Hochberg FH, Benner T, et al. (2010). Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol
28, 2817–2823.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2903316</ArticleId>
            <ArticleId IdType="pubmed">20458050</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Batchelor TT, Mulholland P, Neyns B, Nabors LB, Campone M, Wick A, Mason W, Mikkelsen T, Phuphanich S, Ashby LS, et al. (2013). Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma. J Clin Oncol.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4021043</ArticleId>
            <ArticleId IdType="pubmed">23940216</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M, et al. (2007). AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma Patients. Cancer Cell
11, 83–95.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2748664</ArticleId>
            <ArticleId IdType="pubmed">17222792</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bates DO, Cui TG, Doughty JM, Winkler M, Sugiono M, Shields JD, Peat D, Gillatt D, and Harper SJ (2002). VEGF(165)b, an Inhibitory Splice Variant of Vascular Endothelial Growth Factor, Is Down-Regulated in Renal Cell Carcinoma. Cancer Res
62, 4123–4131.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12124351</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bennouna J, Sastre J, Arnold D, Osterlund P, Greil R, Van Cutsem E, von Moos R, Vieitez JM, Bouche O, Borg C, et al. (2013). Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol
14, 29–37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23168366</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bergers G, and Hanahan D (2008). Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer
8, 592–603.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2874834</ArticleId>
            <ArticleId IdType="pubmed">18650835</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Berlin J, Bendell JC, Hart LL, Firdaus I, Gore I, Hermann RC, Mulcahy MF, Zalupski MM, Mackey HM, Yauch RL, et al. (2013). A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer. Clin Cancer Res
19, 258–267.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23082002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bhutto IA, McLeod DS, Hasegawa T, Kim SY, Merges C, Tong P, and Lutty GA (2006). Pigment epitheliumderived factor (PEDF) and vascular endothelial growth factor (VEGF) in aged human choroid and eyes with age-related macular degeneration. Exp Eye Res
82, 99–110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4932847</ArticleId>
            <ArticleId IdType="pubmed">16019000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Birkenhauer E, and Neethirajan S (2015). A double-edged sword: the role of VEGF in wound repair and chemoattraction of opportunist pathogens. Int J Mol Sci
16, 7159–7172.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4425010</ArticleId>
            <ArticleId IdType="pubmed">25830483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Borgstrom P, Hillan KJ, Sriramarao P, and Ferrara N (1996). Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Research
56, 4032–4039.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8752175</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bressler SB, Ayala AR, Bressler NM, Melia M, Qin H, Ferris FL 3rd, Flaxel CJ, Friedman SM, Glassman AR, Jampol LM, et al. (2016). Persistent Macular Thickening After Ranibizumab Treatment for Diabetic Macular Edema With Vision Impairment. JAMA Ophthalmol
134, 278–285.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4786449</ArticleId>
            <ArticleId IdType="pubmed">26746868</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brown DM, Nguyen QD, Marcus DM, Boyer DS, Patel S, Feiner L, Schlottmann PG, Rundle AC, Zhang J, Rubio RG, et al. (2013). Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology
120, 2013–2022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23706949</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Buehler A, Sitaras N, Favret S, Bucher F, Berger S, Pielen A, Joyal JS, Juan AM, Martin G, Schlunck G, et al. (2013). Semaphorin 3F forms an anti-angiogenic barrier in outer retina. FEBS Lett
587, 1650–1655.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4016712</ArticleId>
            <ArticleId IdType="pubmed">23603393</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Calippe B, Augustin S, Beguier F, Charles-Messance H, Poupel L, Conart JB, Hu SJ, Lavalette S, Fauvet A, Rayes J, et al. (2017). Complement Factor H Inhibits CD47-Mediated Resolution of Inflammation. Immunity
46, 261–272.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28228282</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Calvo P, Ferreras A, Al Adel F, Wang Y, and Brent MH (2015). Dexamethasone intravitreal implant as adjunct therapy for patients with wet age-related macular degeneration with incomplete response to ranibizumab. Br J Ophthalmol
99, 723–726.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25425713</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Campochiaro PA, Khanani A, Singer M, Patel S, Boyer D, Dugel P, Kherani S, Withers B, Gambino L, Peters K, et al. (2016). Enhanced Benefit in Diabetic Macular Edema from AKB-9778 Tie2 Activation Combined with Vascular Endothelial Growth Factor Suppression. Ophthalmology
123, 1722–1730.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27236272</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Campochiaro PA, and Peters KG (2016). Targeting Tie2 for Treatment of Diabetic Retinopathy and Diabetic Macular Edema. Curr Diab Rep
16, 126.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27778249</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caprara C, and Grimm C (2012). From oxygen to erythropoietin: relevance of hypoxia for retinal development, health and disease. Prog Retin Eye Res
31, 89–119.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22108059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoeck A, Harpal K, Eberhardt C, et al. (1996). Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature
380, 435–439
issn: 0028–0836.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8602241</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carrel A (1913). Artificial Activation of the Growth in Vitro of Connective Tissue. J Exp Med
17, 14–19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2125019</ArticleId>
            <ArticleId IdType="pubmed">19867620</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Casanovas O, Hicklin DJ, Bergers G, and Hanahan D (2005). Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell
8, 299–309.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16226705</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chaudhary V, Barbosa J, Lam WC, Mak M, Mavrikakis E, and Mohaghegh PS (2016). Ozurdex in age-related macular degeneration as adjunct to ranibizumab (The OARA Study). Can J Ophthalmol
51, 302–305.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27521672</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chauhan VP, Stylianopoulos T, Martin JD, Popovic Z, Chen O, Kamoun WS, Bawendi MG, Fukumura D, and Jain RK (2012). Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat Nanotechnol
7, 383–388.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3370066</ArticleId>
            <ArticleId IdType="pubmed">22484912</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen DS, and Hurwitz H (2018). Combinations of Bevacizumab With Cancer Immunotherapy. Cancer J
24, 193–204.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30119083</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen DS, and Mellman I (2013). Oncology meets immunology: the cancer-immunity cycle. Immunity
39, 1–10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23890059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen DS, and Mellman I (2017). Elements of cancer immunity and the cancer-immune set point. Nature
541, 321–330.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28102259</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chung AS, and Ferrara N (2011). Developmental and pathological angiogenesis. Annu Rev Cell Dev Biol
27, 563–584.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21756109</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chung AS, Lee J, and Ferrara N (2010). Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer
10, 505–514.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20574450</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chung AS, Wu X, Zhuang G, Ngu H, Kasman I, Zhang J, Vernes JM, Jiang Z, Meng YG, Peale FV, et al. (2013). An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nat Med
19, 1114–1123.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23913124</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Combadiere C, Feumi C, Raoul W, Keller N, Rodero M, Pezard A, Lavalette S, Houssier M, Jonet L, Picard E, et al. (2007). CX3CR1-dependent subretinal microglia cell accumulation is associated with cardinal features of age-related macular degeneration. J Clin Invest
117, 2920–2928.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1994614</ArticleId>
            <ArticleId IdType="pubmed">17909628</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Comparison of Age-related Macular Degeneration Treatments Trials Research, G., Maguire MG, Martin DF, Ying GS, Jaffe GJ, Daniel E, Grunwald JE, Toth CA, Ferris FL 3rd, and Fine SL (2016). Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology
123, 1751–1761.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4958614</ArticleId>
            <ArticleId IdType="pubmed">27156698</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalton HJ, Pradeep S, McGuire M, Hailemichael Y, Ma S, Lyons Y, Armaiz-Pena GN, Previs RA, Hansen JM, Rupaimoole R, et al. (2017). Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression. Clin Cancer Res
23, 7034–7046.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5690831</ArticleId>
            <ArticleId IdType="pubmed">28855350</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Bock K, Georgiadou M, and Carmeliet P (2013). Role of endothelial cell metabolism in vessel sprouting. Cell Metab
18, 634–647.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23973331</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Palma M, Biziato D, and Petrova TV (2017). Microenvironmental regulation of tumour angiogenesis. Nat Rev Cancer
17, 457–474.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28706266</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, and Williams LT (1992). The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science
255, 989–991.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1312256</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diabetic Retinopathy Clinical Research, N., Elman, Qin, Aiello, Beck, Bressler, Ferris, Glassman, Maturi, and Melia (2012). Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology
119, 2312–2318.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3490003</ArticleId>
            <ArticleId IdType="pubmed">22999634</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diabetic Retinopathy Clinical Research, N., Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, Antoszyk AN, Arnold-Bush B, Baker CW, Bressler NM, et al. (2015). Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med
372, 1193–1203.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4422053</ArticleId>
            <ArticleId IdType="pubmed">25692915</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dong A, Seidel C, Snell D, Ekawardhani S, Ahlskog JK, Baumann M, Shen J, Iwase T, Tian J, Stevens R, et al. (2014). Antagonism of PDGF-BB suppresses subretinal neovascularization and enhances the effects of blocking VEGF-A. Angiogenesis
17, 553–562.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3999311</ArticleId>
            <ArticleId IdType="pubmed">24154861</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dugel PU, Jaffe GJ, Sallstig P, Warburton J, Weichselberger A, Wieland M, and Singerman L (2017). Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial. Ophthalmology
124, 1296–1304.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28551167</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duh E, and Aiello LP (1999). Vascular endothelial growth factor and diabetes: the agonist versus antagonist paradox. Diabetes
48, 1899–1906.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10512352</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duh EJ, Sun JK, and Stitt AW (2017). Diabetic retinopathy: current understanding, mechanisms, and treatment strategies. JCI Insight
2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5518557</ArticleId>
            <ArticleId IdType="pubmed">28724805</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dunn EN, Hariprasad SM, and Sheth VS (2017). An Overview of the Fovista and Rinucumab Trials and the Fate of Anti-PDGF Medications. Ophthalmic Surg Lasers Imaging Retina
48, 100–104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28195611</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eilken HM, and Adams RH (2010). Dynamics of endothelial cell behavior in sprouting angiogenesis. Curr Opin Cell Biol
22, 617–625.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20817428</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elman MJ, Bressler NM, Qin H, Beck RW, Ferris FL 3rd, Friedman SM, Glassman AR, Scott IU, Stockdale CR, Sun JK, et al. (2011). Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology
118, 609–614.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3096445</ArticleId>
            <ArticleId IdType="pubmed">21459214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eswarappa SM, Potdar AA, Koch WJ, Fan Y, Vasu K, Lindner D, Willard B, Graham LM, DiCorleto PE, and Fox PL (2014). Programmed translational readthrough generates antiangiogenic VEGF-Ax. Cell
157, 1605–1618.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4113015</ArticleId>
            <ArticleId IdType="pubmed">24949972</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferrara N (2010). Vascular endothelial growth factor and age-related macular degeneration: from basic science to therapy. Nat Med
16, 1107–1111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20930754</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferrara N (2010. 
). Binding to the extracellular matrix and proteolytic processing: two key mechanisms regulating vascular endothelial growth factor action. Mol Biol Cell
21, 687–690.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2828956</ArticleId>
            <ArticleId IdType="pubmed">20185770</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferrara N (2016). VEGF and Intraocular Neovascularization: From Discovery to Therapy. Transl Vis Sci Technol
5, 10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4790412</ArticleId>
            <ArticleId IdType="pubmed">26981332</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferrara N, and Adamis AP (2016). Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov
15, 385–403.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26775688</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O’Shea KS, Powell-Braxton L, Hillan KJ, and Moore MW (1996). Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature
380, 439–442.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8602242</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferrara N, and Henzel WJ (1989). Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochemical &amp; Biophysical Research Communications
161, 851–858.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2735925</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferrara N, Hillan KJ, Gerber HP, and Novotny W (2004). Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov
3, 391–400.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15136787</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fischer C, Jonckx B, Mazzone M, Zacchigna S, Loges S, Pattarini L, Chorianopoulos E, Liesenborghs L, Koch M, De Mol M, et al. (2007). Anti-PlGF Inhibits Growth of VEGF(R)-Inhibitor-Resistant Tumors without Affecting Healthy Vessels. Cell
131, 463–475.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17981115</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Folkman J (1971). Tumor angiogenesis: therapeutic implications. N Engl J Med
285, 1182–1186.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">4938153</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Folkman J, and Klagsbrun M (1987). Angiogenic factors. Science
235, 442–447.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2432664</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fortune B, Schneck ME, and Adams AJ (1999). Multifocal electroretinogram delays reveal local retinal dysfunction in early diabetic retinopathy. Invest Ophthalmol Vis Sci
40, 2638–2651.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10509661</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fukumura D, Kloepper J, Amoozgar Z, Duda DG, and Jain RK (2018). Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol
15, 325–340.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5921900</ArticleId>
            <ArticleId IdType="pubmed">29508855</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gabrilovich D, Ishida T, Oyama T, Ran S, Kravtsov V, Nadaf S, and Carbone DP (1998). Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood
92, 4150–4166.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9834220</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garcia-Carbonero R, van Cutsem E, Rivera F, Jassem J, Gore I Jr., Tebbutt N, Braiteh F, Argiles G, Wainberg ZA, Funke R, et al. (2017). Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer. Oncologist
22, 375–e330.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5388369</ArticleId>
            <ArticleId IdType="pubmed">28275117</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gasperini JL, Fawzi AA, Khondkaryan A, Lam L, Chong LP, Eliott D, Walsh AC, Hwang J, and Sadda SR (2012). Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation. Br J Ophthalmol
96, 14–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21791509</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Geloneck MM, Chuang AZ, Clark WL, Hunt MG, Norman AA, Packwood EA, Tawansy KA, Mintz-Hittner HA, and Group B-RC (2014). Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmol
132, 1327–1333.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25103848</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gerber HP, and Ferrara N (2005). Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res
65, 671–680.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15705858</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gerber HP, Hillan KJ, Ryan AM, Kowalski J, Keller G-A, Rangell L, Wright BD, Radtke F, Aguet M, and Ferrara N (1999). VEGF is required for growth and survival in neonatal mice. Development
126, 1149–1159.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10021335</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gerhardt H (2008). VEGF and endothelial guidance in angiogenic sprouting. Organogenesis
4, 241–246.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2634329</ArticleId>
            <ArticleId IdType="pubmed">19337404</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gerhardt H, Golding M, Fruttiger M, Ruhrberg C, Lundkvist A, Abramsson A, Jeltsch M, Mitchell C, Alitalo K, Shima D, et al. (2003). VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol
161, 1163–1177.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2172999</ArticleId>
            <ArticleId IdType="pubmed">12810700</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Group CR, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, and Jaffe GJ (2011). Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med
364, 1897–1908.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3157322</ArticleId>
            <ArticleId IdType="pubmed">21526923</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hainsworth JD, Spigel DR, Sosman JA, Burris HA 3rd, Farley C, Cucullu H, Yost K, Hart LL, Sylvester L, Waterhouse DM, et al. (2007). Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: a phase I/II trial. Clin Genitourin Cancer
5, 427–432.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18272024</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harrison WW, Bearse MA Jr., Ng JS, Jewell NP, Barez S, Burger D, Schneck ME, and Adams AJ (2011). Multifocal electroretinograms predict onset of diabetic retinopathy in adult patients with diabetes. Invest Ophthalmol Vis Sci
52, 772–777.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3053106</ArticleId>
            <ArticleId IdType="pubmed">20926810</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hegde PS, Wallin JJ, and Mancao C (2017). Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics. Semin Cancer Biol.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29229461</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heier JS, Kherani S, Desai S, Dugel P, Kaushal S, Cheng SH, Delacono C, Purvis A, Richards S, Le-Halpere A, et al. (2017). Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial. Lancet
390, 50–61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28526489</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hellstrom M, Phng LK, and Gerhardt H (2007). VEGF and Notch signaling: the yin and yang of angiogenic sprouting. Cell Adh Migr
1, 133–136.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2634014</ArticleId>
            <ArticleId IdType="pubmed">19262131</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ho AC, Busbee BG, Regillo CD, Wieland MR, Van Everen SA, Li Z, Rubio RG, Lai P, and Group HS (2014). Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular agerelated macular degeneration. Ophthalmology
121, 2181–2192.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25015215</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E, et al. (2002). VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A
99, 11393–11398.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC123267</ArticleId>
            <ArticleId IdType="pubmed">12177445</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Holz FG, Sadda SR, Busbee B, Chew EY, Mitchell P, Tufail A, Brittain C, Ferrara D, Gray S, Honigberg L, et al. (2018). Efficacy and Safety of Lampalizumab for Geographic Atrophy Due to Age-Related Macular Degeneration: Chroma and Spectri Phase 3 Randomized Clinical Trials. JAMA Ophthalmol
136, 666–677.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6145777</ArticleId>
            <ArticleId IdType="pubmed">29801123</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Holz FG, Tadayoni R, Beatty S, Berger A, Cereda MG, Cortez R, Hoyng CB, Hykin P, Staurenghi G, Heldner S, et al. (2015). Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol
99, 220–226.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4316940</ArticleId>
            <ArticleId IdType="pubmed">25193672</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Houck KA, Leung DW, Rowland AM, Winer J, and Ferrara N (1992). Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J-Biol-Chem
267, 26031–26037.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1464614</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang Y, Stylianopoulos T, Duda DG, Fukumura D, and Jain RK (2013). Benefits of vascular normalization are dose and time dependent--letter. Cancer Res
73, 7144–7146.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3876035</ArticleId>
            <ArticleId IdType="pubmed">24265277</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang Y, Yuan J, Righi E, Kamoun WS, Ancukiewicz M, Nezivar J, Santosuosso M, Martin JD, Martin MR, Vianello F, et al. (2012). Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A
109, 17561–17566.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3491458</ArticleId>
            <ArticleId IdType="pubmed">23045683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ide AG, Baker NH, and Warren SL (1939). Vascularization of the Brown Pearce rabbit epithelioma transplant as seen in the transparent ear chamber. Am J Roentgenol
42, 891–899.</Citation>
        </Reference>
        <Reference>
          <Citation>Incio J, Ligibel JA, McManus DT, Suboj P, Jung K, Kawaguchi K, Pinter M, Babykutty S, Chin SM, Vardam TD, et al. (2018). Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2. Sci Transl Med
10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5936748</ArticleId>
            <ArticleId IdType="pubmed">29540614</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Itatani Y, Kawada K, Yamamoto T, and Sakai Y (2018). Resistance to Anti-Angiogenic Therapy in Cancer-Alterations to Anti-VEGF Pathway. Int J Mol Sci
19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5979390</ArticleId>
            <ArticleId IdType="pubmed">29670046</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jaffe GJ, Ciulla TA, Ciardella AP, Devin F, Dugel PU, Eandi CM, Masonson H, Mones J, Pearlman JA, Quaranta-El Maftouhi M, et al. (2017). Dual Antagonism of PDGF and VEGF in Neovascular Age-Related Macular Degeneration: A Phase IIb, Multicenter, Randomized Controlled Trial. Ophthalmology
124, 224–234.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28029445</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jager RD, Mieler WF, and Miller JW (2008). Age-related macular degeneration. N Engl J Med
358, 2606–2617.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18550876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jain RK (2003). Molecular regulation of vessel maturation. Nat Med
9, 685–693.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12778167</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jain RK (2005). Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science
307, 58–62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15637262</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jain RK (2014). Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell
26, 605–622.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4269830</ArticleId>
            <ArticleId IdType="pubmed">25517747</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jayson GC, Kerbel R, Ellis LM, and Harris AL (2016). Antiangiogenic therapy in oncology: current status and future directions. Lancet
388, 518–529.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26853587</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Joyal JS, Omri S, Sitaras N, Rivera JC, Sapieha P, and Chemtob S (2012). Neovascularization in retinopathy of prematurity: opposing actions of neuronal factors GPR91 and semaphorins 3A. Acta Paediatr
101, 819–826.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22497252</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jung K, Heishi T, Khan OF, Kowalski PS, Incio J, Rahbari NN, Chung E, Clark JW, Willett CG, Luster AD, et al. (2017). Ly6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy. J Clin Invest
127, 3039–3051.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5531423</ArticleId>
            <ArticleId IdType="pubmed">28691930</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Junttila MR, and de Sauvage FJ (2013). Influence of tumour micro-environment heterogeneity on therapeutic response. Nature
501, 346–354.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24048067</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kamoun WS, Ley CD, Farrar CT, Duyverman AM, Lahdenranta J, Lacorre DA, Batchelor TT, di Tomaso E, Duda DG, Munn LL, et al. (2009). Edema Control by Cediranib, a Vascular Endothelial Growth Factor Receptor-Targeted Kinase Inhibitor, Prolongs Survival Despite Persistent Brain Tumor Growth in Mice. J Clin Oncol.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2739611</ArticleId>
            <ArticleId IdType="pubmed">19332720</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J, and Connolly DT (1989). Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science
246, 1309–1312.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2479987</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kelly J, Ali Khan A, Yin J, Ferguson TA, and Apte RS (2007). Senescence regulates macrophage activation and angiogenic fate at sites of tissue injury in mice. J Clin Invest
117, 3421–3426.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2045608</ArticleId>
            <ArticleId IdType="pubmed">17975672</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kelly PN (2018). The Cancer Immunotherapy Revolution. Science
359, 1344–1345.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29567702</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kerbel RS (2008). Tumor angiogenesis. N Engl J Med
358, 2039–2049.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4542009</ArticleId>
            <ArticleId IdType="pubmed">18463380</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khan KA, and Kerbel RS (2018). Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. Nat Rev Clin Oncol
15, 310–324.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29434333</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim IK, Husain D, Michaud N, Connolly E, Lane AM, Durrani K, Hafezi-Moghadam A, Gragoudas ES, O’Neill C A, Beyer JC, et al. (2006). Effect of Intravitreal Injection of Ranibizumab in Combination with Verteporfin PDT on Normal Primate Retina and Choroid. Invest Ophthalmol Vis Sci
47, 357–363.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16384985</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim KJ, Li B, Houck K, Winer J, and Ferrara N (1992). The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors
7, 53–64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1380254</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, and Ferrara N (1993). Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature
362, 841–844.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7683111</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P, and Kerbel RS (2000). Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity [see comments]. Journal of Clinical Investigation
105, R15–24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC517491</ArticleId>
            <ArticleId IdType="pubmed">10772661</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kloepper J, Riedemann L, Amoozgar Z, Seano G, Susek K, Yu V, Dalvie N, Amelung RL, Datta M, Song JW, et al. (2016). Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival. Proc Natl Acad Sci U S A
113, 4476–4481.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4843473</ArticleId>
            <ArticleId IdType="pubmed">27044098</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kopetz S, Hoff PM, Morris JS, Wolff RA, Eng C, Glover KY, Adinin R, Overman MJ, Valero V, Wen S, et al. (2010). Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol
28, 453–459.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2815707</ArticleId>
            <ArticleId IdType="pubmed">20008624</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lassen U, Chinot OL, McBain C, Mau-Sorensen M, Larsen VA, Barrie M, Roth P, Krieter O, Wang K, Habben K, et al. (2015). Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma. Neuro Oncol
17, 1007–1015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5654352</ArticleId>
            <ArticleId IdType="pubmed">25665807</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>LeCouter J, Moritz DR, Li B, Phillips GL, Liang XH, Gerber HP, Hillan KJ, and Ferrara N (2003). Angiogenesis-independent endothelial protection of liver: role of VEGFR-1. Science
299, 890–893.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12574630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee CG, Heijn M, di Tomaso E, Griffon-Etienne G, Ancukiewicz M, Koike C, Park KR, Ferrara N, Jain RK, Suit HD, et al. (2000). Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res
60, 5565–5570.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11034104</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leung DW, Cachianes G, Kuang WJ, Goeddel DV, and Ferrara N (1989). Vascular endothelial growth factor is a secreted angiogenic mitogen. Science
246, 1306–1309.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2479986</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li X, Padhan N, Sjostrom EO, Roche FP, Testini C, Honkura N, Sainz-Jaspeado M, Gordon E, Bentley K, Philippides A, et al. (2016). VEGFR2 pY949 signalling regulates adherens junction integrity and metastatic spread. Nat Commun
7, 11017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4814575</ArticleId>
            <ArticleId IdType="pubmed">27005951</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lima e Silva R, Shen J, Hackett SF, Kachi S, Akiyama H, Kiuchi K, Yokoi K, Hatara MC, Lauer T, Aslam S, et al. (2007). The SDF-1/CXCR4 ligand/receptor pair is an important contributor to several types of ocular neovascularization. FASEB J
21, 3219–3230.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17522382</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Long D, Kanan Y, Shen J, Hackett SF, Liu Y, Hafiz Z, Khan M, Lu L, and Campochiaro PA (2018). VEGF/VEGFR2 blockade does not cause retinal atrophy in AMD-relevant models. JCI Insight
3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6012504</ArticleId>
            <ArticleId IdType="pubmed">29769445</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma W, and Wong WT (2016). Aging Changes in Retinal Microglia and their Relevance to Age-related Retinal Disease. Adv Exp Med Biol
854, 73–78.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4696750</ArticleId>
            <ArticleId IdType="pubmed">26427396</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maclachlan TK, Lukason M, Collins M, Munger R, Isenberger E, Rogers C, Malatos S, Dufresne E, Morris J, Calcedo R, et al. (2011). Preclinical safety evaluation of AAV2-sFLT01- a gene therapy for age-related macular degeneration. Mol Ther
19, 326–334.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3034852</ArticleId>
            <ArticleId IdType="pubmed">21119620</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Macosko EZ, Basu A, Satija R, Nemesh J, Shekhar K, Goldman M, Tirosh I, Bialas AR, Kamitaki N, Martersteck EM, et al. (2015). Highly Parallel Genome-wide Expression Profiling of Individual Cells Using Nanoliter Droplets. Cell
161, 1202–1214.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4481139</ArticleId>
            <ArticleId IdType="pubmed">26000488</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW, Pal SK, Reeves JA, et al. (2018). Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med
24, 749–757.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6721896</ArticleId>
            <ArticleId IdType="pubmed">29867230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Michaelson IC (1948). The mode of development of the vascular system of the retina with some observations on its significance for certain retinal disorders. Trans Ophthalmol Soc UK
68, 137–180.</Citation>
        </Reference>
        <Reference>
          <Citation>Miller JW (1997). Vascular endothelial growth factor and ocular neovascularization. Am J Pathol
151, 13–23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1857918</ArticleId>
            <ArticleId IdType="pubmed">9212726</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miller JW, Le Couter J, Strauss EC, and Ferrara N (2013). Vascular endothelial growth factor a in intraocular vascular disease. Ophthalmology
120, 106–114.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23031671</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mintz-Hittner HA, Kennedy KA, Chuang AZ, and Group B-RC (2011). Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med
364, 603–615.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3119530</ArticleId>
            <ArticleId IdType="pubmed">21323540</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mitamura T, Pradeep S, McGuire M, Wu SY, Ma S, Hatakeyama H, Lyons YA, Hisamatsu T, Noh K, Villar-Prados A, et al. (2018). Induction of anti-VEGF therapy resistance by upregulated expression of microseminoprotein (MSMP). Oncogene
37, 722–731.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6040890</ArticleId>
            <ArticleId IdType="pubmed">29059175</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mitsuhashi A, Goto H, Saijo A, Trung VT, Aono Y, Ogino H, Kuramoto T, Tabata S, Uehara H, Izumi K, et al. (2015). Fibrocyte-like cells mediate acquired resistance to anti-angiogenic therapy with bevacizumab. Nat Commun
6, 8792.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4686833</ArticleId>
            <ArticleId IdType="pubmed">26635184</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Motz GT, and Coukos G (2013). Deciphering and reversing tumor immune suppression. Immunity
39, 61–73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3782392</ArticleId>
            <ArticleId IdType="pubmed">23890064</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nagy JA, Chang SH, Dvorak AM, and Dvorak HF (2009). Why are tumour blood vessels abnormal and why is it important to know?
Br J Cancer
100, 865–869.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2661770</ArticleId>
            <ArticleId IdType="pubmed">19240721</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakamura R, Sene A, Santeford A, Gdoura A, Kubota S, Zapata N, and Apte RS (2015). IL10-driven STAT3 signalling in senescent macrophages promotes pathological eye angiogenesis. Nat Commun
6, 7847.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4918330</ArticleId>
            <ArticleId IdType="pubmed">26260587</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Negri L, and Ferrara N (2018). The Prokineticins: Neuromodulators and Mediators of Inflammation and Myeloid Cell-Dependent Angiogenesis. Physiol Rev
98, 1055–1082.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29537336</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nguyen QD, De Falco S, Behar-Cohen F, Lam WC, Li X, Reichhart N, Ricci F, Pluim J, and Li WW (2018). Placental growth factor and its potential role in diabetic retinopathy and other ocular neovascular diseases. Acta Ophthalmol
96, e1–e9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5811779</ArticleId>
            <ArticleId IdType="pubmed">27874278</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ohm JE, and Carbone DP (2001). VEGF as a mediator of tumor-associated immunodeficiency. Immunol Res
23, 263–272.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11444391</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okabe K, Kobayashi S, Yamada T, Kurihara T, Tai-Nagara I, Miyamoto T, Mukouyama YS, Sato TN, Suda T, Ema M, et al. (2014). Neurons limit angiogenesis by titrating VEGF in retina. Cell
159, 584–596.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25417109</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oladipupo SS, Smith C, Santeford A, Park C, Sene A, Wiley LA, Osei-Owusu P, Hsu J, Zapata N, Liu F, et al. (2014). Endothelial cell FGF signaling is required for injury response but not for vascular homeostasis. Proc Natl Acad Sci U S A
111, 13379–13384.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4169958</ArticleId>
            <ArticleId IdType="pubmed">25139991</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Olsson AK, Dimberg A, Kreuger J, and Claesson-Welsh L (2006). VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol
7, 359–371.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16633338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ott PA, Hodi FS, and Buchbinder EI (2015). Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data. Front Oncol
5, 202.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4585112</ArticleId>
            <ArticleId IdType="pubmed">26442214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pajusola K, Aprelikova O, Korhonen J, Kaipainen A, Pertovaara L, Alitalo R, and Alitalo K (1992). FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines [published erratum appears in Cancer Res 1993 Aug 15;53(16):3845]. Cancer-Res
52, 5738–5743
issn: 0008–5472.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1327515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park JE, Chen HH, Winer J, Houck KA, and Ferrara N (1994). Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J-Biol-Chem
269, 25646–25654
issn: 20021–29258.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7929268</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pastuskovas CV, Mundo EE, Williams SP, Nayak TK, Ho J, Ulufatu S, Clark S, Ross S, Cheng E, Parsons-Reponte K, et al. (2012). Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model. Mol Cancer Ther
11, 752–762.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22222630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Penn JS, Tolman BL, and Henry MM (1994). Oxygen-induced retinopathy in the rat: relationship of retinal nonperfusion to subsequent neovascularization. Invest Ophthalmol Vis Sci
35, 3429–3435.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8056518</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Poltorak Z, Cohen T, Sivan R, Kandelis Y, Spira G, Vlodavsky I, Keshet E, and Neufeld G (1997). VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix. Journal of Biological Chemistry
272, 7151–7158.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9054410</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Potente M, Gerhardt H, and Carmeliet P (2011). Basic and therapeutic aspects of angiogenesis. Cell
146, 873–887.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21925313</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Presta LG, Chen H, O’Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, and Ferrara N (1997). Humanization of an anti-VEGF monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res
57, 4593–4599.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9377574</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rajagopal R, Bligard GW, Zhang S, Yin L, Lukasiewicz P, and Semenkovich CF (2016). Functional Deficits Precede Structural Lesions in Mice With High-Fat Diet-Induced Diabetic Retinopathy. Diabetes
65, 1072–1084.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5166563</ArticleId>
            <ArticleId IdType="pubmed">26740595</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rakoczy EP, Lai CM, Magno AL, Wikstrom ME, French MA, Pierce CM, Schwartz SD, Blumenkranz MS, Chalberg TW, Degli-Esposti MA, et al. (2015). Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 year follow-up of a phase 1 randomised clinical trial. Lancet
386, 2395–2403.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26431823</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Regula JT, Lundh von Leithner P, Foxton R, Barathi VA, Cheung CM, Bo Tun SB, Wey YS, Iwata D, Dostalek M, Moelleken J, et al. (2016). Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases. EMBO Mol Med
8, 1265–1288.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5090659</ArticleId>
            <ArticleId IdType="pubmed">27742718</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ruhrberg C, Gerhardt H, Golding M, Watson R, Ioannidou S, Fujisawa H, Betsholtz C, and Shima DT (2002). Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis. Genes Dev
16, 2684–2698.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC187458</ArticleId>
            <ArticleId IdType="pubmed">12381667</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saharinen P, Eklund L, and Alitalo K (2017). Therapeutic targeting of the angiopoietin-TIE pathway. Nat Rev Drug Discov
16, 635–661.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28529319</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saint-Geniez M, Kurihara T, Sekiyama E, Maldonado AE, and D’Amore PA (2009). An essential role for RPEderived soluble VEGF in the maintenance of the choriocapillaris. Proc Natl Acad Sci U S A
106, 18751–18756.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2774033</ArticleId>
            <ArticleId IdType="pubmed">19841260</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sakurai Y, Ohgimoto K, Kataoka Y, Yoshida N, and Shibuya M (2005). Essential role of Flk-1 (VEGF receptor 2) tyrosine residue 1173 in vasculogenesis in mice. Proc Natl Acad Sci U S A
102, 1076–1081.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC545830</ArticleId>
            <ArticleId IdType="pubmed">15644447</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schmittnaegel M, Rigamonti N, Kadioglu E, Cassara A, Wyser Rmili C, Kiialainen A, Kienast Y, Mueller HJ, Ooi CH, Laoui D, et al. (2017). Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade. Sci Transl Med
9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28404865</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scott IU, VanVeldhuisen PC, Ip MS, Blodi BA, Oden NL, Awh CC, Kunimoto DY, Marcus DM, Wroblewski JJ, King J, et al. (2017). Effect of Bevacizumab vs Aflibercept on Visual Acuity Among Patients With Macular Edema Due to Central Retinal Vein Occlusion: The SCORE2 Randomized Clinical Trial. JAMA
317, 2072–2087.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5710547</ArticleId>
            <ArticleId IdType="pubmed">28492910</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Segarra M, Ohnuki H, Maric D, Salvucci O, Hou X, Kumar A, Li X, and Tosato G (2012). Semaphorin 6A regulates angiogenesis by modulating VEGF signaling. Blood
120, 4104–4115.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3496961</ArticleId>
            <ArticleId IdType="pubmed">23007403</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Semenza GL (2000a). HIF-1: mediator of physiological and pathophysiological response to hypoxia. J Appl Physiolol
88, 1474–1480.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10749844</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Semenza GL (2000b). HIF-1: using two hands to flip the angiogenic switch. Cancer Metastasis Rev
19, 59–65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11191064</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sene A, and Apte RS (2014). Eyeballing cholesterol efflux and macrophage function in disease pathogenesis. Trends Endocrinol Metab
25, 107–114.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3943676</ArticleId>
            <ArticleId IdType="pubmed">24252662</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sene A, Chin-Yee D, and Apte RS (2015). Seeing through VEGF: innate and adaptive immunity in pathological angiogenesis in the eye. Trends Mol Med
21, 43–51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4282831</ArticleId>
            <ArticleId IdType="pubmed">25457617</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sene A, Khan AA, Cox D, Nakamura RE, Santeford A, Kim BM, Sidhu R, Onken MD, Harbour JW, Hagbi-Levi S, et al. (2013). Impaired cholesterol efflux in senescent macrophages promotes age-related macular degeneration. Cell Metab
17, 549–561.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3640261</ArticleId>
            <ArticleId IdType="pubmed">23562078</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Senger DR, Connolly DT, Van de Water L, Feder J, and Dvorak HF (1990). Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Research
50, 1774–1778.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2155059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, and Dvorak HF (1983). Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science
219, 983–985.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6823562</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sepah YJ, Sadiq MA, Boyer D, Callanan D, Gallemore R, Bennett M, Marcus D, Halperin L, Hassan M, Campochiaro PA, et al. (2016). Twenty-four-Month Outcomes of the Ranibizumab for Edema of the Macula in Diabetes - Protocol 3 with High Dose (READ-3) Study. Ophthalmology
123, 2581–2587.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27707550</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML, and Schuh AC (1995). Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature
376, 62–66.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7596435</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shojaei F, Wu X, Malik AK, Zhong C, Baldwin ME, Schanz S, Fuh G, Gerber HP, and Ferrara N (2007). Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol
25, 911–920.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17664940</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shojaei F, Wu X, Qu X, Kowanetz M, Yu L, Tan M, Meng YG, and Ferrara N (2009). G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc Natl Acad Sci U S A
106, 6742–6747.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2665197</ArticleId>
            <ArticleId IdType="pubmed">19346489</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shrimali RK, Yu Z, Theoret MR, Chinnasamy D, Restifo NP, and Rosenberg SA (2010). Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res
70, 6171–6180.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2912959</ArticleId>
            <ArticleId IdType="pubmed">20631075</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smith LE (2003). Pathogenesis of retinopathy of prematurity. Semin Neonatol
8, 469–473.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15001119</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smith LE, Wesolowski E, McLellan A, Kostyk SK, D’Amato R, Sullivan R, and D’Amore PA (1994). Oxygeninduced retinopathy in the mouse. Invest Ophthalmol Vis Sci
35, 101–111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7507904</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Snuderl M, Batista A, Kirkpatrick ND, Ruiz de Almodovar C, Riedemann L, Walsh EC, Anolik R, Huang Y, Martin JD, Kamoun W, et al. (2013). Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma. Cell
152, 1065–1076.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3587980</ArticleId>
            <ArticleId IdType="pubmed">23452854</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodriguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, et al. (2018). Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med
378, 2288–2301.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29863955</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soker S, Takashima S, Miao HQ, Neufeld G, and Klagsbrun M (1998). Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell
92, 735–745.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9529250</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sonmez K, Drenser KA, Capone A Jr., and Trese MT (2008). Vitreous levels of stromal cell-derived factor 1 and vascular endothelial growth factor in patients with retinopathy of prematurity. Ophthalmology
115, 1065–1070 e1061.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18031819</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spooner K, Hong T, Bahrami B, and Chang A (2018). A meta-analysis of patients with treatment-resistant macular oedema secondary to retinal vein occlusions following switching to aflibercept. Acta Ophthalmol.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30251325</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stepien KE, Rosenfeld PJ, Puliafito CA, Feuer W, Shi W, Al-Attar L, Dubovy SR, Murray TG, Davis JL, Lee WH, et al. (2009). Comparison of intravitreal bevacizumab followed by ranibizumab for the treatment of neovascular age-related macular degeneration. Retina
29, 1067–1073.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19696701</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sweeney CJ, Miller KD, Sissons SE, Nozaki S, Heilman DK, Shen J, and Sledge GW Jr. (2001). The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res
61, 3369–3372.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11309294</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Terman BI, Dougher Vermazen M, Carrion ME, Dimitrov D, Armellino DC, Gospodarowicz D, and Bohlen P (1992). Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem-Biophys-Res-Commun
187, 1579–1586
issn: 0006–1291x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1417831</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, and Jain RK (2004). Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res
64, 3731–3736.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15172975</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van der Veldt AA, Lubberink M, Bahce I, Walraven M, de Boer MP, Greuter HN, Hendrikse NH, Eriksson J, Windhorst AD, Postmus PE, et al. (2012). Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs. Cancer Cell
21, 82–91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22264790</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wacker A, and Gerhardt H (2011). Endothelial development taking shape. Curr Opin Cell Biol
23, 676–685.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22051380</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P, Kehoe SM, Johannessen CM, Macconaill LE, Hahn WC, et al. (2011). Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling. J Clin Oncol.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3157968</ArticleId>
            <ArticleId IdType="pubmed">21383288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wakelee H, Zvirbule Z, De Braud F, Kingsley CD, Mekhail T, Lowe T, Schutte W, Lena H, Lawler W, Braiteh F, et al. (2017). Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Non-Squamous Non-Small-Cell Lung Cancer. Clin Lung Cancer
18, 50–59.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27856142</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wallin JJ, Bendell JC, Funke R, Sznol M, Korski K, Jones S, Hernandez G, Mier J, He X, Hodi FS, et al. (2016). Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. Nat Commun
7, 12624.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5013615</ArticleId>
            <ArticleId IdType="pubmed">27571927</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Warren RS, Yuan H, Matli MR, Gillett NA, and Ferrara N (1995). Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J-Clin-Invest
95, 1789–1797
issn: 0021–9738.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC295707</ArticleId>
            <ArticleId IdType="pubmed">7535799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wechsler-Reya RJ, and Barres BA (1997). Retinal development: communication helps you see the light. Curr Biol
7, R433–436.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9210366</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weekes CD, Beeram M, Tolcher AW, Papadopoulos KP, Gore L, Hegde P, Xin Y, Yu R, Shih LM, Xiang H, et al. (2014). A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors. Invest New Drugs
32, 653–660.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24604265</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weekes CD, Rosen LS, Capasso A, Wong KM, Ye W, Anderson M, McCall B, Fredrickson J, Wakshull E, Eppler S, et al. (2018). Phase I study of the anti-alpha5beta1 monoclonal antibody MINT1526A with or without bevacizumab in patients with advanced solid tumors. Cancer Chemother Pharmacol
82, 339–351.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29905898</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Willett CG, Boucher Y, Di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, et al. (2004). Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med
10, 145–147.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2693485</ArticleId>
            <ArticleId IdType="pubmed">14745444</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, Xu L, Hicklin DJ, Fukumura D, di Tomaso E, et al. (2004). Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell
6, 553–563.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15607960</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wise GN (1956). Retinal neovascularization. Trans Am Ophthalmol Soc
54, 729–826.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1312655</ArticleId>
            <ArticleId IdType="pubmed">13433795</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Writing Committee for the Diabetic Retinopathy Clinical Research, N., Gross, Glassman AR, Jampol LM, Inusah S, Aiello LP, Antoszyk AN, Baker CW, Berger BB, Bressler NM, et al. (2015). Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial. JAMA
314, 2137–2146.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5567801</ArticleId>
            <ArticleId IdType="pubmed">26565927</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xin H, Zhong C, Nudleman E, and Ferrara N (2016). Evidence for Pro-angiogenic Functions of VEGF-Ax. Cell
167, 275–284 e276.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27662093</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang S, Toy K, Ingle G, Zlot C, Williams PM, Fuh G, Li B, de Vos A, and Gerritsen ME (2002). Vascular endothelial growth factor-induced genes in human umbilical vein endothelial cells: relative roles of KDR and Flt-1 receptors. Arterioscler Thromb Vasc Biol
22, 1797–1803.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12426207</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yao J, Wu X, Zhuang G, Kasman IM, Vogt T, Phan V, Shibuya M, Ferrara N, and Bais C (2011). Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy. Proc Natl Acad Sci U S A
108, 11590–11595.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3136309</ArticleId>
            <ArticleId IdType="pubmed">21709213</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yaspan BL, Williams DF, Holz FG, Regillo CD, Li Z, Dressen A, van Lookeren Campagne M, Le KN, Graham RR, Beres T, et al. (2017). Targeting factor D of the alternative complement pathway reduces geographic atrophy progression secondary to age-related macular degeneration. Sci Transl Med
9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28637922</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yonekawa Y, Andreoli C, Miller JB, Loewenstein JI, Sobrin L, Eliott D, Vavvas DG, Miller JW, and Kim IK (2013). Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration. Am J Ophthalmol
156, 29–35 e22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23668679</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zirlik K, and Duyster J (2018). Anti-Angiogenics: Current Situation and Future Perspectives. Oncol Res Treat
41, 166–171.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29562226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zissen MH, Kunz P, Subbarayan M, Chin FT, Conti PS, Fisher GA, and Quon A (2011). 18F-5-fluorouracil dynamic positron emission tomography/computed tomography shows decreased tracer activity after bevacizumab in colorectal metastases. Nucl Med Commun
32, 343–347.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21412178</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">30849371</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>01</Month>
        <Day>06</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>03</Month>
        <Day>09</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1097-4172</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>176</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2019</Year>
              <Month>Mar</Month>
              <Day>07</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cell</Title>
          <ISOAbbreviation>Cell</ISOAbbreviation>
        </Journal>
        <ArticleTitle>VEGF in Signaling and Disease: Beyond Discovery and Development.</ArticleTitle>
        <Pagination>
          <StartPage>1248</StartPage>
          <EndPage>1264</EndPage>
          <MedlinePgn>1248-1264</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cell.2019.01.021</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0092-8674(19)30054-6</ELocationID>
        <Abstract>
          <AbstractText>The discovery of vascular endothelial-derived growth factor (VEGF) has revolutionized our understanding of vasculogenesis and angiogenesis during development and physiological homeostasis. Over a short span of two decades, our understanding of the molecular mechanisms by which VEGF coordinates neurovascular homeostasis has become more sophisticated. The central role of VEGF in the pathogenesis of diverse cancers and blinding eye diseases has also become evident. Elucidation of the molecular regulation of VEGF and the transformative development of multiple therapeutic pathways targeting VEGF directly or indirectly is a powerful case study of how fundamental research can guide innovation and translation. It is also an elegant example of how agnostic discovery and can transform our understanding of human disease. This review will highlight critical nodal points in VEGF biology, including recent developments in immunotherapy for cancer and multitarget approaches in neovascular eye disease.</AbstractText>
          <CopyrightInformation>Copyright © 2019 Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Apte</LastName>
            <ForeName>Rajendra S</ForeName>
            <Initials>RS</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, MO, USA; Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA; Department of Developmental Biology, Washington University School of Medicine, St. Louis, MO, USA. Electronic address: apte@wustl.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Daniel S</ForeName>
            <Initials>DS</Initials>
            <AffiliationInfo>
              <Affiliation>IGM Biosciences, Mountain View, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ferrara</LastName>
            <ForeName>Napoleone</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, University of California, San Diego, CA, USA; Department of Ophthalmology, University of California, San Diego, CA, USA; The Moores Cancer Center, University of California, San Diego, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>P30 EY002687</GrantID>
            <Acronym>EY</Acronym>
            <Agency>NEI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 EY019287</GrantID>
            <Acronym>EY</Acronym>
            <Agency>NEI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R21 EY026707</GrantID>
            <Acronym>EY</Acronym>
            <Agency>NEI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R21 EY028701</GrantID>
            <Acronym>EY</Acronym>
            <Agency>NEI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Cell</MedlineTA>
        <NlmUniqueID>0413066</NlmUniqueID>
        <ISSNLinking>0092-8674</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D042461">Vascular Endothelial Growth Factor A</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D042442">Vascular Endothelial Growth Factors</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012171" MajorTopicYN="N">Retinal Vessels</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D042461" MajorTopicYN="N">Vascular Endothelial Growth Factor A</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D042442" MajorTopicYN="N">Vascular Endothelial Growth Factors</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2018</Year>
          <Month>9</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2019</Year>
          <Month>1</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2019</Year>
          <Month>1</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pmc-release">
          <Year>2020</Year>
          <Month>3</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>3</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>3</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>1</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">30849371</ArticleId>
        <ArticleId IdType="mid">NIHMS1518667</ArticleId>
        <ArticleId IdType="pmc">PMC6410740</ArticleId>
        <ArticleId IdType="doi">10.1016/j.cell.2019.01.021</ArticleId>
        <ArticleId IdType="pii">S0092-8674(19)30054-6</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Adamis AP, and Shima DT (2005). The role of vascular endothelial growth factor in ocular health and disease. Retina
25, 111–118.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15689799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Algire GH, Chalkley HW, Legallais FY, and Park HD (1945). Vascular reactions of normal and malignant tissues in vivo. I. Vascular reactions of mice to wounds and to normal and neoplastic transplants. J Natl Cancer Inst
6, 73–85.</Citation>
        </Reference>
        <Reference>
          <Citation>Alitalo K, Tammela T, and Petrova TV (2005). Lymphangiogenesis in development and human disease. Nature
438, 946–953.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16355212</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Allen E, Jabouille A, Rivera LB, Lodewijckx I, Missiaen R, Steri V, Feyen K, Tawney J, Hanahan D, Michael IP, et al. (2017). Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation. Sci Transl Med
9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5554432</ArticleId>
            <ArticleId IdType="pubmed">28404866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Apte RS (2016). What Is Chronic or Persistent Diabetic Macular Edema and How Should It Be Treated?
JAMA Ophthalmol
134, 285–286.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26746003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Apte RS (2018). Gene Therapy for Retinal Degeneration. Cell
173, 5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29570997</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Apte RS, Richter J, Herndon J, and Ferguson TA (2006). Macrophages inhibit neovascularization in a murine model of age-related macular degeneration. PLoS Med
3, e310.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1539093</ArticleId>
            <ArticleId IdType="pubmed">16903779</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arjaans M, Oosting SF, Schroder CP, and de Vries EG (2013). Bevacizumab-induced vessel normalization hampers tumor uptake of antibodies--response. Cancer Res
73, 7147–7148.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24265275</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ashton N (1952). Observations on the choroidal circulation. Br J Ophthalmol
36, 465–481.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1323969</ArticleId>
            <ArticleId IdType="pubmed">12978221</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ashton N (1966). Oxygen and the growth and development of retinal vessels. In vivo and in vitro studies. The XX Francis I. Proctor Lecture. Am J Ophthalmol
62, 412–435.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">5950745</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Atkins MB, Clark JI, and Quinn DI (2017). Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions. Ann Oncol
28, 1484–1494.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28383639</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Atkins MB, Plimack ER, Puzanov I, Fishman MN, McDermott DF, Cho DC, Vaishampayan U, George S, Olencki TE, Tarazi JC, et al. (2018). Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial. Lancet Oncol
19, 405–415.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6860026</ArticleId>
            <ArticleId IdType="pubmed">29439857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Augustin HG, Koh GY, Thurston G, and Alitalo K (2009). Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol
10, 165–177.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19234476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bais C, Wu X, Yao J, Yang S, Crawford Y, McCutcheon K, Tan C, Koluman G, Vernes J-M, Eastham-Anderson J, et al. (2010). PlGF blockade does not inhibit angiogenesis during primary tumor growth. Cell
141, 166–177.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20371352</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bakall B, Folk JC, Boldt HC, Sohn EH, Stone EM, Russell SR, and Mahajan VB (2013). Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab. Am J Ophthalmol
156, 15–22 e11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23706500</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ban N, Lee TJ, Sene A, Choudhary M, Lekwuwa M, Dong Z, Santeford A, Lin JB, Malek G, Ory DS, et al. (2018). Impaired monocyte cholesterol clearance initiates age-related retinal degeneration and vision loss. JCI Insight
3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6171801</ArticleId>
            <ArticleId IdType="pubmed">30185655</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A, and Marme D (1996). Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood
87, 3336–3343.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8605350</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, Eichler AF, Drappatz J, Hochberg FH, Benner T, et al. (2010). Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol
28, 2817–2823.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2903316</ArticleId>
            <ArticleId IdType="pubmed">20458050</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Batchelor TT, Mulholland P, Neyns B, Nabors LB, Campone M, Wick A, Mason W, Mikkelsen T, Phuphanich S, Ashby LS, et al. (2013). Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma. J Clin Oncol.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4021043</ArticleId>
            <ArticleId IdType="pubmed">23940216</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M, et al. (2007). AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma Patients. Cancer Cell
11, 83–95.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2748664</ArticleId>
            <ArticleId IdType="pubmed">17222792</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bates DO, Cui TG, Doughty JM, Winkler M, Sugiono M, Shields JD, Peat D, Gillatt D, and Harper SJ (2002). VEGF(165)b, an Inhibitory Splice Variant of Vascular Endothelial Growth Factor, Is Down-Regulated in Renal Cell Carcinoma. Cancer Res
62, 4123–4131.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12124351</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bennouna J, Sastre J, Arnold D, Osterlund P, Greil R, Van Cutsem E, von Moos R, Vieitez JM, Bouche O, Borg C, et al. (2013). Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol
14, 29–37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23168366</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bergers G, and Hanahan D (2008). Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer
8, 592–603.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2874834</ArticleId>
            <ArticleId IdType="pubmed">18650835</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Berlin J, Bendell JC, Hart LL, Firdaus I, Gore I, Hermann RC, Mulcahy MF, Zalupski MM, Mackey HM, Yauch RL, et al. (2013). A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer. Clin Cancer Res
19, 258–267.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23082002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bhutto IA, McLeod DS, Hasegawa T, Kim SY, Merges C, Tong P, and Lutty GA (2006). Pigment epitheliumderived factor (PEDF) and vascular endothelial growth factor (VEGF) in aged human choroid and eyes with age-related macular degeneration. Exp Eye Res
82, 99–110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4932847</ArticleId>
            <ArticleId IdType="pubmed">16019000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Birkenhauer E, and Neethirajan S (2015). A double-edged sword: the role of VEGF in wound repair and chemoattraction of opportunist pathogens. Int J Mol Sci
16, 7159–7172.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4425010</ArticleId>
            <ArticleId IdType="pubmed">25830483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Borgstrom P, Hillan KJ, Sriramarao P, and Ferrara N (1996). Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Research
56, 4032–4039.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8752175</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bressler SB, Ayala AR, Bressler NM, Melia M, Qin H, Ferris FL 3rd, Flaxel CJ, Friedman SM, Glassman AR, Jampol LM, et al. (2016). Persistent Macular Thickening After Ranibizumab Treatment for Diabetic Macular Edema With Vision Impairment. JAMA Ophthalmol
134, 278–285.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4786449</ArticleId>
            <ArticleId IdType="pubmed">26746868</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brown DM, Nguyen QD, Marcus DM, Boyer DS, Patel S, Feiner L, Schlottmann PG, Rundle AC, Zhang J, Rubio RG, et al. (2013). Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology
120, 2013–2022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23706949</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Buehler A, Sitaras N, Favret S, Bucher F, Berger S, Pielen A, Joyal JS, Juan AM, Martin G, Schlunck G, et al. (2013). Semaphorin 3F forms an anti-angiogenic barrier in outer retina. FEBS Lett
587, 1650–1655.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4016712</ArticleId>
            <ArticleId IdType="pubmed">23603393</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Calippe B, Augustin S, Beguier F, Charles-Messance H, Poupel L, Conart JB, Hu SJ, Lavalette S, Fauvet A, Rayes J, et al. (2017). Complement Factor H Inhibits CD47-Mediated Resolution of Inflammation. Immunity
46, 261–272.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28228282</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Calvo P, Ferreras A, Al Adel F, Wang Y, and Brent MH (2015). Dexamethasone intravitreal implant as adjunct therapy for patients with wet age-related macular degeneration with incomplete response to ranibizumab. Br J Ophthalmol
99, 723–726.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25425713</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Campochiaro PA, Khanani A, Singer M, Patel S, Boyer D, Dugel P, Kherani S, Withers B, Gambino L, Peters K, et al. (2016). Enhanced Benefit in Diabetic Macular Edema from AKB-9778 Tie2 Activation Combined with Vascular Endothelial Growth Factor Suppression. Ophthalmology
123, 1722–1730.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27236272</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Campochiaro PA, and Peters KG (2016). Targeting Tie2 for Treatment of Diabetic Retinopathy and Diabetic Macular Edema. Curr Diab Rep
16, 126.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27778249</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caprara C, and Grimm C (2012). From oxygen to erythropoietin: relevance of hypoxia for retinal development, health and disease. Prog Retin Eye Res
31, 89–119.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22108059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoeck A, Harpal K, Eberhardt C, et al. (1996). Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature
380, 435–439
issn: 0028–0836.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8602241</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carrel A (1913). Artificial Activation of the Growth in Vitro of Connective Tissue. J Exp Med
17, 14–19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2125019</ArticleId>
            <ArticleId IdType="pubmed">19867620</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Casanovas O, Hicklin DJ, Bergers G, and Hanahan D (2005). Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell
8, 299–309.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16226705</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chaudhary V, Barbosa J, Lam WC, Mak M, Mavrikakis E, and Mohaghegh PS (2016). Ozurdex in age-related macular degeneration as adjunct to ranibizumab (The OARA Study). Can J Ophthalmol
51, 302–305.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27521672</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chauhan VP, Stylianopoulos T, Martin JD, Popovic Z, Chen O, Kamoun WS, Bawendi MG, Fukumura D, and Jain RK (2012). Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat Nanotechnol
7, 383–388.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3370066</ArticleId>
            <ArticleId IdType="pubmed">22484912</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen DS, and Hurwitz H (2018). Combinations of Bevacizumab With Cancer Immunotherapy. Cancer J
24, 193–204.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30119083</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen DS, and Mellman I (2013). Oncology meets immunology: the cancer-immunity cycle. Immunity
39, 1–10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23890059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen DS, and Mellman I (2017). Elements of cancer immunity and the cancer-immune set point. Nature
541, 321–330.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28102259</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chung AS, and Ferrara N (2011). Developmental and pathological angiogenesis. Annu Rev Cell Dev Biol
27, 563–584.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21756109</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chung AS, Lee J, and Ferrara N (2010). Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer
10, 505–514.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20574450</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chung AS, Wu X, Zhuang G, Ngu H, Kasman I, Zhang J, Vernes JM, Jiang Z, Meng YG, Peale FV, et al. (2013). An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nat Med
19, 1114–1123.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23913124</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Combadiere C, Feumi C, Raoul W, Keller N, Rodero M, Pezard A, Lavalette S, Houssier M, Jonet L, Picard E, et al. (2007). CX3CR1-dependent subretinal microglia cell accumulation is associated with cardinal features of age-related macular degeneration. J Clin Invest
117, 2920–2928.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1994614</ArticleId>
            <ArticleId IdType="pubmed">17909628</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Comparison of Age-related Macular Degeneration Treatments Trials Research, G., Maguire MG, Martin DF, Ying GS, Jaffe GJ, Daniel E, Grunwald JE, Toth CA, Ferris FL 3rd, and Fine SL (2016). Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology
123, 1751–1761.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4958614</ArticleId>
            <ArticleId IdType="pubmed">27156698</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalton HJ, Pradeep S, McGuire M, Hailemichael Y, Ma S, Lyons Y, Armaiz-Pena GN, Previs RA, Hansen JM, Rupaimoole R, et al. (2017). Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression. Clin Cancer Res
23, 7034–7046.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5690831</ArticleId>
            <ArticleId IdType="pubmed">28855350</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Bock K, Georgiadou M, and Carmeliet P (2013). Role of endothelial cell metabolism in vessel sprouting. Cell Metab
18, 634–647.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23973331</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Palma M, Biziato D, and Petrova TV (2017). Microenvironmental regulation of tumour angiogenesis. Nat Rev Cancer
17, 457–474.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28706266</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, and Williams LT (1992). The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science
255, 989–991.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1312256</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diabetic Retinopathy Clinical Research, N., Elman, Qin, Aiello, Beck, Bressler, Ferris, Glassman, Maturi, and Melia (2012). Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology
119, 2312–2318.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3490003</ArticleId>
            <ArticleId IdType="pubmed">22999634</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diabetic Retinopathy Clinical Research, N., Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, Antoszyk AN, Arnold-Bush B, Baker CW, Bressler NM, et al. (2015). Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med
372, 1193–1203.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4422053</ArticleId>
            <ArticleId IdType="pubmed">25692915</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dong A, Seidel C, Snell D, Ekawardhani S, Ahlskog JK, Baumann M, Shen J, Iwase T, Tian J, Stevens R, et al. (2014). Antagonism of PDGF-BB suppresses subretinal neovascularization and enhances the effects of blocking VEGF-A. Angiogenesis
17, 553–562.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3999311</ArticleId>
            <ArticleId IdType="pubmed">24154861</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dugel PU, Jaffe GJ, Sallstig P, Warburton J, Weichselberger A, Wieland M, and Singerman L (2017). Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial. Ophthalmology
124, 1296–1304.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28551167</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duh E, and Aiello LP (1999). Vascular endothelial growth factor and diabetes: the agonist versus antagonist paradox. Diabetes
48, 1899–1906.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10512352</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duh EJ, Sun JK, and Stitt AW (2017). Diabetic retinopathy: current understanding, mechanisms, and treatment strategies. JCI Insight
2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5518557</ArticleId>
            <ArticleId IdType="pubmed">28724805</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dunn EN, Hariprasad SM, and Sheth VS (2017). An Overview of the Fovista and Rinucumab Trials and the Fate of Anti-PDGF Medications. Ophthalmic Surg Lasers Imaging Retina
48, 100–104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28195611</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eilken HM, and Adams RH (2010). Dynamics of endothelial cell behavior in sprouting angiogenesis. Curr Opin Cell Biol
22, 617–625.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20817428</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elman MJ, Bressler NM, Qin H, Beck RW, Ferris FL 3rd, Friedman SM, Glassman AR, Scott IU, Stockdale CR, Sun JK, et al. (2011). Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology
118, 609–614.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3096445</ArticleId>
            <ArticleId IdType="pubmed">21459214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eswarappa SM, Potdar AA, Koch WJ, Fan Y, Vasu K, Lindner D, Willard B, Graham LM, DiCorleto PE, and Fox PL (2014). Programmed translational readthrough generates antiangiogenic VEGF-Ax. Cell
157, 1605–1618.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4113015</ArticleId>
            <ArticleId IdType="pubmed">24949972</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferrara N (2010). Vascular endothelial growth factor and age-related macular degeneration: from basic science to therapy. Nat Med
16, 1107–1111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20930754</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferrara N (2010. 
). Binding to the extracellular matrix and proteolytic processing: two key mechanisms regulating vascular endothelial growth factor action. Mol Biol Cell
21, 687–690.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2828956</ArticleId>
            <ArticleId IdType="pubmed">20185770</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferrara N (2016). VEGF and Intraocular Neovascularization: From Discovery to Therapy. Transl Vis Sci Technol
5, 10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4790412</ArticleId>
            <ArticleId IdType="pubmed">26981332</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferrara N, and Adamis AP (2016). Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov
15, 385–403.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26775688</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O’Shea KS, Powell-Braxton L, Hillan KJ, and Moore MW (1996). Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature
380, 439–442.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8602242</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferrara N, and Henzel WJ (1989). Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochemical &amp; Biophysical Research Communications
161, 851–858.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2735925</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferrara N, Hillan KJ, Gerber HP, and Novotny W (2004). Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov
3, 391–400.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15136787</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fischer C, Jonckx B, Mazzone M, Zacchigna S, Loges S, Pattarini L, Chorianopoulos E, Liesenborghs L, Koch M, De Mol M, et al. (2007). Anti-PlGF Inhibits Growth of VEGF(R)-Inhibitor-Resistant Tumors without Affecting Healthy Vessels. Cell
131, 463–475.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17981115</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Folkman J (1971). Tumor angiogenesis: therapeutic implications. N Engl J Med
285, 1182–1186.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">4938153</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Folkman J, and Klagsbrun M (1987). Angiogenic factors. Science
235, 442–447.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2432664</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fortune B, Schneck ME, and Adams AJ (1999). Multifocal electroretinogram delays reveal local retinal dysfunction in early diabetic retinopathy. Invest Ophthalmol Vis Sci
40, 2638–2651.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10509661</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fukumura D, Kloepper J, Amoozgar Z, Duda DG, and Jain RK (2018). Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol
15, 325–340.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5921900</ArticleId>
            <ArticleId IdType="pubmed">29508855</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gabrilovich D, Ishida T, Oyama T, Ran S, Kravtsov V, Nadaf S, and Carbone DP (1998). Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood
92, 4150–4166.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9834220</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garcia-Carbonero R, van Cutsem E, Rivera F, Jassem J, Gore I Jr., Tebbutt N, Braiteh F, Argiles G, Wainberg ZA, Funke R, et al. (2017). Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer. Oncologist
22, 375–e330.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5388369</ArticleId>
            <ArticleId IdType="pubmed">28275117</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gasperini JL, Fawzi AA, Khondkaryan A, Lam L, Chong LP, Eliott D, Walsh AC, Hwang J, and Sadda SR (2012). Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation. Br J Ophthalmol
96, 14–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21791509</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Geloneck MM, Chuang AZ, Clark WL, Hunt MG, Norman AA, Packwood EA, Tawansy KA, Mintz-Hittner HA, and Group B-RC (2014). Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmol
132, 1327–1333.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25103848</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gerber HP, and Ferrara N (2005). Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res
65, 671–680.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15705858</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gerber HP, Hillan KJ, Ryan AM, Kowalski J, Keller G-A, Rangell L, Wright BD, Radtke F, Aguet M, and Ferrara N (1999). VEGF is required for growth and survival in neonatal mice. Development
126, 1149–1159.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10021335</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gerhardt H (2008). VEGF and endothelial guidance in angiogenic sprouting. Organogenesis
4, 241–246.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2634329</ArticleId>
            <ArticleId IdType="pubmed">19337404</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gerhardt H, Golding M, Fruttiger M, Ruhrberg C, Lundkvist A, Abramsson A, Jeltsch M, Mitchell C, Alitalo K, Shima D, et al. (2003). VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol
161, 1163–1177.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2172999</ArticleId>
            <ArticleId IdType="pubmed">12810700</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Group CR, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, and Jaffe GJ (2011). Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med
364, 1897–1908.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3157322</ArticleId>
            <ArticleId IdType="pubmed">21526923</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hainsworth JD, Spigel DR, Sosman JA, Burris HA 3rd, Farley C, Cucullu H, Yost K, Hart LL, Sylvester L, Waterhouse DM, et al. (2007). Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: a phase I/II trial. Clin Genitourin Cancer
5, 427–432.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18272024</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harrison WW, Bearse MA Jr., Ng JS, Jewell NP, Barez S, Burger D, Schneck ME, and Adams AJ (2011). Multifocal electroretinograms predict onset of diabetic retinopathy in adult patients with diabetes. Invest Ophthalmol Vis Sci
52, 772–777.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3053106</ArticleId>
            <ArticleId IdType="pubmed">20926810</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hegde PS, Wallin JJ, and Mancao C (2017). Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics. Semin Cancer Biol.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29229461</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heier JS, Kherani S, Desai S, Dugel P, Kaushal S, Cheng SH, Delacono C, Purvis A, Richards S, Le-Halpere A, et al. (2017). Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial. Lancet
390, 50–61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28526489</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hellstrom M, Phng LK, and Gerhardt H (2007). VEGF and Notch signaling: the yin and yang of angiogenic sprouting. Cell Adh Migr
1, 133–136.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2634014</ArticleId>
            <ArticleId IdType="pubmed">19262131</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ho AC, Busbee BG, Regillo CD, Wieland MR, Van Everen SA, Li Z, Rubio RG, Lai P, and Group HS (2014). Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular agerelated macular degeneration. Ophthalmology
121, 2181–2192.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25015215</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E, et al. (2002). VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A
99, 11393–11398.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC123267</ArticleId>
            <ArticleId IdType="pubmed">12177445</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Holz FG, Sadda SR, Busbee B, Chew EY, Mitchell P, Tufail A, Brittain C, Ferrara D, Gray S, Honigberg L, et al. (2018). Efficacy and Safety of Lampalizumab for Geographic Atrophy Due to Age-Related Macular Degeneration: Chroma and Spectri Phase 3 Randomized Clinical Trials. JAMA Ophthalmol
136, 666–677.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6145777</ArticleId>
            <ArticleId IdType="pubmed">29801123</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Holz FG, Tadayoni R, Beatty S, Berger A, Cereda MG, Cortez R, Hoyng CB, Hykin P, Staurenghi G, Heldner S, et al. (2015). Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol
99, 220–226.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4316940</ArticleId>
            <ArticleId IdType="pubmed">25193672</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Houck KA, Leung DW, Rowland AM, Winer J, and Ferrara N (1992). Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J-Biol-Chem
267, 26031–26037.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1464614</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang Y, Stylianopoulos T, Duda DG, Fukumura D, and Jain RK (2013). Benefits of vascular normalization are dose and time dependent--letter. Cancer Res
73, 7144–7146.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3876035</ArticleId>
            <ArticleId IdType="pubmed">24265277</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang Y, Yuan J, Righi E, Kamoun WS, Ancukiewicz M, Nezivar J, Santosuosso M, Martin JD, Martin MR, Vianello F, et al. (2012). Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A
109, 17561–17566.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3491458</ArticleId>
            <ArticleId IdType="pubmed">23045683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ide AG, Baker NH, and Warren SL (1939). Vascularization of the Brown Pearce rabbit epithelioma transplant as seen in the transparent ear chamber. Am J Roentgenol
42, 891–899.</Citation>
        </Reference>
        <Reference>
          <Citation>Incio J, Ligibel JA, McManus DT, Suboj P, Jung K, Kawaguchi K, Pinter M, Babykutty S, Chin SM, Vardam TD, et al. (2018). Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2. Sci Transl Med
10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5936748</ArticleId>
            <ArticleId IdType="pubmed">29540614</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Itatani Y, Kawada K, Yamamoto T, and Sakai Y (2018). Resistance to Anti-Angiogenic Therapy in Cancer-Alterations to Anti-VEGF Pathway. Int J Mol Sci
19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5979390</ArticleId>
            <ArticleId IdType="pubmed">29670046</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jaffe GJ, Ciulla TA, Ciardella AP, Devin F, Dugel PU, Eandi CM, Masonson H, Mones J, Pearlman JA, Quaranta-El Maftouhi M, et al. (2017). Dual Antagonism of PDGF and VEGF in Neovascular Age-Related Macular Degeneration: A Phase IIb, Multicenter, Randomized Controlled Trial. Ophthalmology
124, 224–234.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28029445</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jager RD, Mieler WF, and Miller JW (2008). Age-related macular degeneration. N Engl J Med
358, 2606–2617.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18550876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jain RK (2003). Molecular regulation of vessel maturation. Nat Med
9, 685–693.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12778167</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jain RK (2005). Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science
307, 58–62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15637262</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jain RK (2014). Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell
26, 605–622.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4269830</ArticleId>
            <ArticleId IdType="pubmed">25517747</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jayson GC, Kerbel R, Ellis LM, and Harris AL (2016). Antiangiogenic therapy in oncology: current status and future directions. Lancet
388, 518–529.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26853587</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Joyal JS, Omri S, Sitaras N, Rivera JC, Sapieha P, and Chemtob S (2012). Neovascularization in retinopathy of prematurity: opposing actions of neuronal factors GPR91 and semaphorins 3A. Acta Paediatr
101, 819–826.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22497252</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jung K, Heishi T, Khan OF, Kowalski PS, Incio J, Rahbari NN, Chung E, Clark JW, Willett CG, Luster AD, et al. (2017). Ly6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy. J Clin Invest
127, 3039–3051.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5531423</ArticleId>
            <ArticleId IdType="pubmed">28691930</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Junttila MR, and de Sauvage FJ (2013). Influence of tumour micro-environment heterogeneity on therapeutic response. Nature
501, 346–354.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24048067</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kamoun WS, Ley CD, Farrar CT, Duyverman AM, Lahdenranta J, Lacorre DA, Batchelor TT, di Tomaso E, Duda DG, Munn LL, et al. (2009). Edema Control by Cediranib, a Vascular Endothelial Growth Factor Receptor-Targeted Kinase Inhibitor, Prolongs Survival Despite Persistent Brain Tumor Growth in Mice. J Clin Oncol.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2739611</ArticleId>
            <ArticleId IdType="pubmed">19332720</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J, and Connolly DT (1989). Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science
246, 1309–1312.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2479987</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kelly J, Ali Khan A, Yin J, Ferguson TA, and Apte RS (2007). Senescence regulates macrophage activation and angiogenic fate at sites of tissue injury in mice. J Clin Invest
117, 3421–3426.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2045608</ArticleId>
            <ArticleId IdType="pubmed">17975672</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kelly PN (2018). The Cancer Immunotherapy Revolution. Science
359, 1344–1345.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29567702</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kerbel RS (2008). Tumor angiogenesis. N Engl J Med
358, 2039–2049.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4542009</ArticleId>
            <ArticleId IdType="pubmed">18463380</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khan KA, and Kerbel RS (2018). Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. Nat Rev Clin Oncol
15, 310–324.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29434333</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim IK, Husain D, Michaud N, Connolly E, Lane AM, Durrani K, Hafezi-Moghadam A, Gragoudas ES, O’Neill C A, Beyer JC, et al. (2006). Effect of Intravitreal Injection of Ranibizumab in Combination with Verteporfin PDT on Normal Primate Retina and Choroid. Invest Ophthalmol Vis Sci
47, 357–363.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16384985</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim KJ, Li B, Houck K, Winer J, and Ferrara N (1992). The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors
7, 53–64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1380254</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, and Ferrara N (1993). Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature
362, 841–844.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7683111</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P, and Kerbel RS (2000). Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity [see comments]. Journal of Clinical Investigation
105, R15–24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC517491</ArticleId>
            <ArticleId IdType="pubmed">10772661</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kloepper J, Riedemann L, Amoozgar Z, Seano G, Susek K, Yu V, Dalvie N, Amelung RL, Datta M, Song JW, et al. (2016). Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival. Proc Natl Acad Sci U S A
113, 4476–4481.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4843473</ArticleId>
            <ArticleId IdType="pubmed">27044098</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kopetz S, Hoff PM, Morris JS, Wolff RA, Eng C, Glover KY, Adinin R, Overman MJ, Valero V, Wen S, et al. (2010). Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol
28, 453–459.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2815707</ArticleId>
            <ArticleId IdType="pubmed">20008624</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lassen U, Chinot OL, McBain C, Mau-Sorensen M, Larsen VA, Barrie M, Roth P, Krieter O, Wang K, Habben K, et al. (2015). Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma. Neuro Oncol
17, 1007–1015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5654352</ArticleId>
            <ArticleId IdType="pubmed">25665807</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>LeCouter J, Moritz DR, Li B, Phillips GL, Liang XH, Gerber HP, Hillan KJ, and Ferrara N (2003). Angiogenesis-independent endothelial protection of liver: role of VEGFR-1. Science
299, 890–893.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12574630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee CG, Heijn M, di Tomaso E, Griffon-Etienne G, Ancukiewicz M, Koike C, Park KR, Ferrara N, Jain RK, Suit HD, et al. (2000). Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res
60, 5565–5570.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11034104</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leung DW, Cachianes G, Kuang WJ, Goeddel DV, and Ferrara N (1989). Vascular endothelial growth factor is a secreted angiogenic mitogen. Science
246, 1306–1309.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2479986</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li X, Padhan N, Sjostrom EO, Roche FP, Testini C, Honkura N, Sainz-Jaspeado M, Gordon E, Bentley K, Philippides A, et al. (2016). VEGFR2 pY949 signalling regulates adherens junction integrity and metastatic spread. Nat Commun
7, 11017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4814575</ArticleId>
            <ArticleId IdType="pubmed">27005951</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lima e Silva R, Shen J, Hackett SF, Kachi S, Akiyama H, Kiuchi K, Yokoi K, Hatara MC, Lauer T, Aslam S, et al. (2007). The SDF-1/CXCR4 ligand/receptor pair is an important contributor to several types of ocular neovascularization. FASEB J
21, 3219–3230.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17522382</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Long D, Kanan Y, Shen J, Hackett SF, Liu Y, Hafiz Z, Khan M, Lu L, and Campochiaro PA (2018). VEGF/VEGFR2 blockade does not cause retinal atrophy in AMD-relevant models. JCI Insight
3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6012504</ArticleId>
            <ArticleId IdType="pubmed">29769445</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma W, and Wong WT (2016). Aging Changes in Retinal Microglia and their Relevance to Age-related Retinal Disease. Adv Exp Med Biol
854, 73–78.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4696750</ArticleId>
            <ArticleId IdType="pubmed">26427396</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maclachlan TK, Lukason M, Collins M, Munger R, Isenberger E, Rogers C, Malatos S, Dufresne E, Morris J, Calcedo R, et al. (2011). Preclinical safety evaluation of AAV2-sFLT01- a gene therapy for age-related macular degeneration. Mol Ther
19, 326–334.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3034852</ArticleId>
            <ArticleId IdType="pubmed">21119620</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Macosko EZ, Basu A, Satija R, Nemesh J, Shekhar K, Goldman M, Tirosh I, Bialas AR, Kamitaki N, Martersteck EM, et al. (2015). Highly Parallel Genome-wide Expression Profiling of Individual Cells Using Nanoliter Droplets. Cell
161, 1202–1214.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4481139</ArticleId>
            <ArticleId IdType="pubmed">26000488</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW, Pal SK, Reeves JA, et al. (2018). Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med
24, 749–757.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6721896</ArticleId>
            <ArticleId IdType="pubmed">29867230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Michaelson IC (1948). The mode of development of the vascular system of the retina with some observations on its significance for certain retinal disorders. Trans Ophthalmol Soc UK
68, 137–180.</Citation>
        </Reference>
        <Reference>
          <Citation>Miller JW (1997). Vascular endothelial growth factor and ocular neovascularization. Am J Pathol
151, 13–23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1857918</ArticleId>
            <ArticleId IdType="pubmed">9212726</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miller JW, Le Couter J, Strauss EC, and Ferrara N (2013). Vascular endothelial growth factor a in intraocular vascular disease. Ophthalmology
120, 106–114.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23031671</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mintz-Hittner HA, Kennedy KA, Chuang AZ, and Group B-RC (2011). Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med
364, 603–615.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3119530</ArticleId>
            <ArticleId IdType="pubmed">21323540</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mitamura T, Pradeep S, McGuire M, Wu SY, Ma S, Hatakeyama H, Lyons YA, Hisamatsu T, Noh K, Villar-Prados A, et al. (2018). Induction of anti-VEGF therapy resistance by upregulated expression of microseminoprotein (MSMP). Oncogene
37, 722–731.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6040890</ArticleId>
            <ArticleId IdType="pubmed">29059175</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mitsuhashi A, Goto H, Saijo A, Trung VT, Aono Y, Ogino H, Kuramoto T, Tabata S, Uehara H, Izumi K, et al. (2015). Fibrocyte-like cells mediate acquired resistance to anti-angiogenic therapy with bevacizumab. Nat Commun
6, 8792.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4686833</ArticleId>
            <ArticleId IdType="pubmed">26635184</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Motz GT, and Coukos G (2013). Deciphering and reversing tumor immune suppression. Immunity
39, 61–73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3782392</ArticleId>
            <ArticleId IdType="pubmed">23890064</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nagy JA, Chang SH, Dvorak AM, and Dvorak HF (2009). Why are tumour blood vessels abnormal and why is it important to know?
Br J Cancer
100, 865–869.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2661770</ArticleId>
            <ArticleId IdType="pubmed">19240721</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakamura R, Sene A, Santeford A, Gdoura A, Kubota S, Zapata N, and Apte RS (2015). IL10-driven STAT3 signalling in senescent macrophages promotes pathological eye angiogenesis. Nat Commun
6, 7847.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4918330</ArticleId>
            <ArticleId IdType="pubmed">26260587</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Negri L, and Ferrara N (2018). The Prokineticins: Neuromodulators and Mediators of Inflammation and Myeloid Cell-Dependent Angiogenesis. Physiol Rev
98, 1055–1082.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29537336</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nguyen QD, De Falco S, Behar-Cohen F, Lam WC, Li X, Reichhart N, Ricci F, Pluim J, and Li WW (2018). Placental growth factor and its potential role in diabetic retinopathy and other ocular neovascular diseases. Acta Ophthalmol
96, e1–e9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5811779</ArticleId>
            <ArticleId IdType="pubmed">27874278</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ohm JE, and Carbone DP (2001). VEGF as a mediator of tumor-associated immunodeficiency. Immunol Res
23, 263–272.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11444391</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okabe K, Kobayashi S, Yamada T, Kurihara T, Tai-Nagara I, Miyamoto T, Mukouyama YS, Sato TN, Suda T, Ema M, et al. (2014). Neurons limit angiogenesis by titrating VEGF in retina. Cell
159, 584–596.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25417109</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oladipupo SS, Smith C, Santeford A, Park C, Sene A, Wiley LA, Osei-Owusu P, Hsu J, Zapata N, Liu F, et al. (2014). Endothelial cell FGF signaling is required for injury response but not for vascular homeostasis. Proc Natl Acad Sci U S A
111, 13379–13384.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4169958</ArticleId>
            <ArticleId IdType="pubmed">25139991</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Olsson AK, Dimberg A, Kreuger J, and Claesson-Welsh L (2006). VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol
7, 359–371.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16633338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ott PA, Hodi FS, and Buchbinder EI (2015). Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data. Front Oncol
5, 202.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4585112</ArticleId>
            <ArticleId IdType="pubmed">26442214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pajusola K, Aprelikova O, Korhonen J, Kaipainen A, Pertovaara L, Alitalo R, and Alitalo K (1992). FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines [published erratum appears in Cancer Res 1993 Aug 15;53(16):3845]. Cancer-Res
52, 5738–5743
issn: 0008–5472.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1327515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park JE, Chen HH, Winer J, Houck KA, and Ferrara N (1994). Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J-Biol-Chem
269, 25646–25654
issn: 20021–29258.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7929268</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pastuskovas CV, Mundo EE, Williams SP, Nayak TK, Ho J, Ulufatu S, Clark S, Ross S, Cheng E, Parsons-Reponte K, et al. (2012). Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model. Mol Cancer Ther
11, 752–762.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22222630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Penn JS, Tolman BL, and Henry MM (1994). Oxygen-induced retinopathy in the rat: relationship of retinal nonperfusion to subsequent neovascularization. Invest Ophthalmol Vis Sci
35, 3429–3435.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8056518</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Poltorak Z, Cohen T, Sivan R, Kandelis Y, Spira G, Vlodavsky I, Keshet E, and Neufeld G (1997). VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix. Journal of Biological Chemistry
272, 7151–7158.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9054410</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Potente M, Gerhardt H, and Carmeliet P (2011). Basic and therapeutic aspects of angiogenesis. Cell
146, 873–887.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21925313</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Presta LG, Chen H, O’Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, and Ferrara N (1997). Humanization of an anti-VEGF monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res
57, 4593–4599.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9377574</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rajagopal R, Bligard GW, Zhang S, Yin L, Lukasiewicz P, and Semenkovich CF (2016). Functional Deficits Precede Structural Lesions in Mice With High-Fat Diet-Induced Diabetic Retinopathy. Diabetes
65, 1072–1084.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5166563</ArticleId>
            <ArticleId IdType="pubmed">26740595</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rakoczy EP, Lai CM, Magno AL, Wikstrom ME, French MA, Pierce CM, Schwartz SD, Blumenkranz MS, Chalberg TW, Degli-Esposti MA, et al. (2015). Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 year follow-up of a phase 1 randomised clinical trial. Lancet
386, 2395–2403.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26431823</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Regula JT, Lundh von Leithner P, Foxton R, Barathi VA, Cheung CM, Bo Tun SB, Wey YS, Iwata D, Dostalek M, Moelleken J, et al. (2016). Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases. EMBO Mol Med
8, 1265–1288.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5090659</ArticleId>
            <ArticleId IdType="pubmed">27742718</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ruhrberg C, Gerhardt H, Golding M, Watson R, Ioannidou S, Fujisawa H, Betsholtz C, and Shima DT (2002). Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis. Genes Dev
16, 2684–2698.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC187458</ArticleId>
            <ArticleId IdType="pubmed">12381667</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saharinen P, Eklund L, and Alitalo K (2017). Therapeutic targeting of the angiopoietin-TIE pathway. Nat Rev Drug Discov
16, 635–661.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28529319</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saint-Geniez M, Kurihara T, Sekiyama E, Maldonado AE, and D’Amore PA (2009). An essential role for RPEderived soluble VEGF in the maintenance of the choriocapillaris. Proc Natl Acad Sci U S A
106, 18751–18756.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2774033</ArticleId>
            <ArticleId IdType="pubmed">19841260</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sakurai Y, Ohgimoto K, Kataoka Y, Yoshida N, and Shibuya M (2005). Essential role of Flk-1 (VEGF receptor 2) tyrosine residue 1173 in vasculogenesis in mice. Proc Natl Acad Sci U S A
102, 1076–1081.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC545830</ArticleId>
            <ArticleId IdType="pubmed">15644447</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schmittnaegel M, Rigamonti N, Kadioglu E, Cassara A, Wyser Rmili C, Kiialainen A, Kienast Y, Mueller HJ, Ooi CH, Laoui D, et al. (2017). Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade. Sci Transl Med
9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28404865</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scott IU, VanVeldhuisen PC, Ip MS, Blodi BA, Oden NL, Awh CC, Kunimoto DY, Marcus DM, Wroblewski JJ, King J, et al. (2017). Effect of Bevacizumab vs Aflibercept on Visual Acuity Among Patients With Macular Edema Due to Central Retinal Vein Occlusion: The SCORE2 Randomized Clinical Trial. JAMA
317, 2072–2087.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5710547</ArticleId>
            <ArticleId IdType="pubmed">28492910</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Segarra M, Ohnuki H, Maric D, Salvucci O, Hou X, Kumar A, Li X, and Tosato G (2012). Semaphorin 6A regulates angiogenesis by modulating VEGF signaling. Blood
120, 4104–4115.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3496961</ArticleId>
            <ArticleId IdType="pubmed">23007403</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Semenza GL (2000a). HIF-1: mediator of physiological and pathophysiological response to hypoxia. J Appl Physiolol
88, 1474–1480.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10749844</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Semenza GL (2000b). HIF-1: using two hands to flip the angiogenic switch. Cancer Metastasis Rev
19, 59–65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11191064</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sene A, and Apte RS (2014). Eyeballing cholesterol efflux and macrophage function in disease pathogenesis. Trends Endocrinol Metab
25, 107–114.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3943676</ArticleId>
            <ArticleId IdType="pubmed">24252662</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sene A, Chin-Yee D, and Apte RS (2015). Seeing through VEGF: innate and adaptive immunity in pathological angiogenesis in the eye. Trends Mol Med
21, 43–51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4282831</ArticleId>
            <ArticleId IdType="pubmed">25457617</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sene A, Khan AA, Cox D, Nakamura RE, Santeford A, Kim BM, Sidhu R, Onken MD, Harbour JW, Hagbi-Levi S, et al. (2013). Impaired cholesterol efflux in senescent macrophages promotes age-related macular degeneration. Cell Metab
17, 549–561.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3640261</ArticleId>
            <ArticleId IdType="pubmed">23562078</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Senger DR, Connolly DT, Van de Water L, Feder J, and Dvorak HF (1990). Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Research
50, 1774–1778.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2155059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, and Dvorak HF (1983). Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science
219, 983–985.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6823562</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sepah YJ, Sadiq MA, Boyer D, Callanan D, Gallemore R, Bennett M, Marcus D, Halperin L, Hassan M, Campochiaro PA, et al. (2016). Twenty-four-Month Outcomes of the Ranibizumab for Edema of the Macula in Diabetes - Protocol 3 with High Dose (READ-3) Study. Ophthalmology
123, 2581–2587.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27707550</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML, and Schuh AC (1995). Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature
376, 62–66.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7596435</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shojaei F, Wu X, Malik AK, Zhong C, Baldwin ME, Schanz S, Fuh G, Gerber HP, and Ferrara N (2007). Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol
25, 911–920.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17664940</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shojaei F, Wu X, Qu X, Kowanetz M, Yu L, Tan M, Meng YG, and Ferrara N (2009). G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc Natl Acad Sci U S A
106, 6742–6747.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2665197</ArticleId>
            <ArticleId IdType="pubmed">19346489</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shrimali RK, Yu Z, Theoret MR, Chinnasamy D, Restifo NP, and Rosenberg SA (2010). Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res
70, 6171–6180.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2912959</ArticleId>
            <ArticleId IdType="pubmed">20631075</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smith LE (2003). Pathogenesis of retinopathy of prematurity. Semin Neonatol
8, 469–473.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15001119</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smith LE, Wesolowski E, McLellan A, Kostyk SK, D’Amato R, Sullivan R, and D’Amore PA (1994). Oxygeninduced retinopathy in the mouse. Invest Ophthalmol Vis Sci
35, 101–111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7507904</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Snuderl M, Batista A, Kirkpatrick ND, Ruiz de Almodovar C, Riedemann L, Walsh EC, Anolik R, Huang Y, Martin JD, Kamoun W, et al. (2013). Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma. Cell
152, 1065–1076.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3587980</ArticleId>
            <ArticleId IdType="pubmed">23452854</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodriguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, et al. (2018). Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med
378, 2288–2301.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29863955</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soker S, Takashima S, Miao HQ, Neufeld G, and Klagsbrun M (1998). Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell
92, 735–745.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9529250</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sonmez K, Drenser KA, Capone A Jr., and Trese MT (2008). Vitreous levels of stromal cell-derived factor 1 and vascular endothelial growth factor in patients with retinopathy of prematurity. Ophthalmology
115, 1065–1070 e1061.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18031819</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spooner K, Hong T, Bahrami B, and Chang A (2018). A meta-analysis of patients with treatment-resistant macular oedema secondary to retinal vein occlusions following switching to aflibercept. Acta Ophthalmol.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30251325</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stepien KE, Rosenfeld PJ, Puliafito CA, Feuer W, Shi W, Al-Attar L, Dubovy SR, Murray TG, Davis JL, Lee WH, et al. (2009). Comparison of intravitreal bevacizumab followed by ranibizumab for the treatment of neovascular age-related macular degeneration. Retina
29, 1067–1073.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19696701</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sweeney CJ, Miller KD, Sissons SE, Nozaki S, Heilman DK, Shen J, and Sledge GW Jr. (2001). The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res
61, 3369–3372.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11309294</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Terman BI, Dougher Vermazen M, Carrion ME, Dimitrov D, Armellino DC, Gospodarowicz D, and Bohlen P (1992). Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem-Biophys-Res-Commun
187, 1579–1586
issn: 0006–1291x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1417831</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, and Jain RK (2004). Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res
64, 3731–3736.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15172975</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van der Veldt AA, Lubberink M, Bahce I, Walraven M, de Boer MP, Greuter HN, Hendrikse NH, Eriksson J, Windhorst AD, Postmus PE, et al. (2012). Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs. Cancer Cell
21, 82–91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22264790</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wacker A, and Gerhardt H (2011). Endothelial development taking shape. Curr Opin Cell Biol
23, 676–685.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22051380</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P, Kehoe SM, Johannessen CM, Macconaill LE, Hahn WC, et al. (2011). Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling. J Clin Oncol.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3157968</ArticleId>
            <ArticleId IdType="pubmed">21383288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wakelee H, Zvirbule Z, De Braud F, Kingsley CD, Mekhail T, Lowe T, Schutte W, Lena H, Lawler W, Braiteh F, et al. (2017). Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Non-Squamous Non-Small-Cell Lung Cancer. Clin Lung Cancer
18, 50–59.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27856142</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wallin JJ, Bendell JC, Funke R, Sznol M, Korski K, Jones S, Hernandez G, Mier J, He X, Hodi FS, et al. (2016). Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. Nat Commun
7, 12624.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5013615</ArticleId>
            <ArticleId IdType="pubmed">27571927</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Warren RS, Yuan H, Matli MR, Gillett NA, and Ferrara N (1995). Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J-Clin-Invest
95, 1789–1797
issn: 0021–9738.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC295707</ArticleId>
            <ArticleId IdType="pubmed">7535799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wechsler-Reya RJ, and Barres BA (1997). Retinal development: communication helps you see the light. Curr Biol
7, R433–436.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9210366</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weekes CD, Beeram M, Tolcher AW, Papadopoulos KP, Gore L, Hegde P, Xin Y, Yu R, Shih LM, Xiang H, et al. (2014). A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors. Invest New Drugs
32, 653–660.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24604265</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weekes CD, Rosen LS, Capasso A, Wong KM, Ye W, Anderson M, McCall B, Fredrickson J, Wakshull E, Eppler S, et al. (2018). Phase I study of the anti-alpha5beta1 monoclonal antibody MINT1526A with or without bevacizumab in patients with advanced solid tumors. Cancer Chemother Pharmacol
82, 339–351.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29905898</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Willett CG, Boucher Y, Di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, et al. (2004). Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med
10, 145–147.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2693485</ArticleId>
            <ArticleId IdType="pubmed">14745444</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, Xu L, Hicklin DJ, Fukumura D, di Tomaso E, et al. (2004). Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell
6, 553–563.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15607960</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wise GN (1956). Retinal neovascularization. Trans Am Ophthalmol Soc
54, 729–826.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1312655</ArticleId>
            <ArticleId IdType="pubmed">13433795</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Writing Committee for the Diabetic Retinopathy Clinical Research, N., Gross, Glassman AR, Jampol LM, Inusah S, Aiello LP, Antoszyk AN, Baker CW, Berger BB, Bressler NM, et al. (2015). Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial. JAMA
314, 2137–2146.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5567801</ArticleId>
            <ArticleId IdType="pubmed">26565927</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xin H, Zhong C, Nudleman E, and Ferrara N (2016). Evidence for Pro-angiogenic Functions of VEGF-Ax. Cell
167, 275–284 e276.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27662093</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang S, Toy K, Ingle G, Zlot C, Williams PM, Fuh G, Li B, de Vos A, and Gerritsen ME (2002). Vascular endothelial growth factor-induced genes in human umbilical vein endothelial cells: relative roles of KDR and Flt-1 receptors. Arterioscler Thromb Vasc Biol
22, 1797–1803.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12426207</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yao J, Wu X, Zhuang G, Kasman IM, Vogt T, Phan V, Shibuya M, Ferrara N, and Bais C (2011). Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy. Proc Natl Acad Sci U S A
108, 11590–11595.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3136309</ArticleId>
            <ArticleId IdType="pubmed">21709213</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yaspan BL, Williams DF, Holz FG, Regillo CD, Li Z, Dressen A, van Lookeren Campagne M, Le KN, Graham RR, Beres T, et al. (2017). Targeting factor D of the alternative complement pathway reduces geographic atrophy progression secondary to age-related macular degeneration. Sci Transl Med
9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28637922</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yonekawa Y, Andreoli C, Miller JB, Loewenstein JI, Sobrin L, Eliott D, Vavvas DG, Miller JW, and Kim IK (2013). Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration. Am J Ophthalmol
156, 29–35 e22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23668679</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zirlik K, and Duyster J (2018). Anti-Angiogenics: Current Situation and Future Perspectives. Oncol Res Treat
41, 166–171.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29562226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zissen MH, Kunz P, Subbarayan M, Chin FT, Conti PS, Fisher GA, and Quon A (2011). 18F-5-fluorouracil dynamic positron emission tomography/computed tomography shows decreased tracer activity after bevacizumab in colorectal metastases. Nucl Med Commun
32, 343–347.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21412178</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
